Stock comparison
AbbVie Inc. is 410.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($453.11 B vs $1.10 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
ABBV is larger
AbbVie Inc. is 410.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($453.11 B vs $1.10 B).
Market value leader
ABBV
AbbVie Inc. is 410.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($453.11 B vs $1.10 B).
Profit leader
ABBV
MLTX: -$227.32M vs ABBV: $4.23B.
| Metric | MLTX | ABBV |
|---|---|---|
| Market cap | $1.10 B | $453.11 B |
| US-listed rank | #2554 | #24 |
| Revenue (latest FY) | - | $61.16B |
| Net income (latest FY) | -$227.32M | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 107.2x |
| SEC filings | 296 | 1,008 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
AbbVie Inc. is 410.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($453.11 B vs $1.10 B).
Full pages: MoonLake Immunotherapeutics and AbbVie Inc., or browse the full rankings.